Get the Stockscreener App
31.68
11.00%
3.14
Pre-market:
31.01
-0.67
-2.11%
Monopar Therapeutics Inc stock is traded at $31.68, with a volume of 30,978.
It is up +11.00% in the last 24 hours and up +22.70% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$28.54
Open:
$28.6
24h Volume:
30,978
Relative Volume:
0.06
Market Cap:
$193.33M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-13.77
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+26.82%
1M Performance:
+22.70%
6M Performance:
+4,593%
1Y Performance:
+8,544%
1-Day Range:
$28.60
$32.52
1-Week Range:
$24.00
$32.52
52-Week Range:
$0.309
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
31.68 | 193.33M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN
(MNPR) Trading Report - Stock Traders Daily
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - TradingView
Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Piper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - MSN
(MNPR) Trading Advice - Stock Traders Daily
Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Brookline Capital Management Comments on MNPR Q1 Earnings - Defense World
Brookline Capital Management Predicts MNPR Q1 Earnings - MarketBeat
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Monopar Therapeutics Inc - GuruFocus.com
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - MSN
How the (MNPR) price action is used to our Advantage - Stock Traders Daily
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025 - Yahoo Finance
Monopar Therapeutics Inc. Enters Into Underwritten Registered Offering and Concurrent Private PlacementOn December 20, 2024, Monopar Therapeutics Inc. (NASDAQ: MNPR) finalized an Underwriting Agreement with Piper Sandler & Co. to conduct an Und - Defense World
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks Investment Research
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways (MNPR) - Seeking Alpha
(MNPR) Technical Data - Stock Traders Daily
Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants - The Manila Times
Monopar Therapeutics sets stock and warrant offering prices - Investing.com
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength - MSN
When the Price of (MNPR) Talks, People Listen - Stock Traders Daily
Monopar Therapeutics Achieves Milestone in Cancer Treatment - TipRanks
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu - EIN News
Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu - Marketscreener.com
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' - MSN
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
3 Momentum Stocks Soaring Into 2025 and Beyond - sharewise
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus - Seeking Alpha
(MNPR) Proactive Strategies - Stock Traders Daily
HC Wainwright Has Positive Estimate for MNPR FY2024 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal By Investing.com - Investing.com UK
Monopar Therapeutics (NASDAQ:MNPR) Releases Financial Results for the Third Quarter 2024Monopar Therapeutics Inc. recently disclosed its financial results for the third quarter ending September 30, 2024, in a press release dated November 8, 2024. The - Defense World
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
(MNPR) Investment Report - Stock Traders Daily
Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -$0.37 and Net Loss of $1.3 Million - GuruFocus.com
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - GlobeNewswire Inc.
Janus Henderson Group PLC Acquires New Stake in Monopar Therapeu - GuruFocus.com
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Manila Times
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):